Ergosta-4,6,8(14),22-tetraen-3-one isolated from<i>Polyporus umbellatus</i>prevents early renal injury in aristolochic acid-induced nephropathy rats

Zhao, Ying-Yong; Zhang, Li; Mao, Jiarong; Cheng, Xin; Lin, Rui‐Chao; Zhang, Yongmin; Sun, Wenli

doi:10.1111/j.2042-7158.2011.01361.x

Cited by 54 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other also demonstrate that YMGKI-2 possesses pharmacological activities in vivo and in vitro [54–57]. Together, these studies suggest that YMGKI-2 is a potential drug for disease treatment.…”

Section: Discussionmentioning

confidence: 82%

Targeting cancer initiating cells by promoting cell differentiation and restoring chemosensitivity via dual inactivation of STAT3 and Src activity using an active component of Antrodia cinnamomea mycelia

Chang¹,

Chen²,

Chen

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Cancer initiating cells (CICs) represent a subpopulation of cancer cells, which are responsible for tumor growth and resistance to chemotherapy. Herein, we first used a cell-based aldehyde dehydrogenase (ALDH) activity assay to identify that YMGKI-2 (also named as Ergone), an active component purified from Antrodia cinnamomea Mycelia extract (ACME), effectively abrogated the ALDH activity and abolished the CICs in head and neck squamous cell carcinoma cells (HNSCCs). Consequently, YMGKI-2 treatment suppressed self-renewal ability and expression of stemness signature genes (Oct-4 and Nanog) of sphere cells with enriched CICs. Moreover, YMGKI-2 treated sphere cells displayed reduction of CICs properties and promotion of cell differentiation, but not significant cytotoxicity. YMGKI-2 treatment also attenuated the tumorigenicity of HNSCC cells in vivo. Mechanistically, treatment of YMGKI-2 resulted in inactivation of STAT3 and Src. Lastly, combinatorial treatments with YMGKI-2 and standard chemotherapeutic drugs (cisplatin or Fluorouracil) restored the chemosensivity on sphere cells and cisplatin-resistant HNSCC cells. Together, we demonstrate that YMGKI-2 treatment effectively induces differentiation and reduces tumorigenicity of CICs. Further, combined treatment of YMGKI-2 and conventional chemotherapy can overcome chemoresistance. These results suggest that YMGKI-2 treatment may be used to improve future clinical responses in head and neck cancer treatment through targeting CICs.

show abstract

Section: Discussionmentioning

confidence: 82%

Targeting cancer initiating cells by promoting cell differentiation and restoring chemosensitivity via dual inactivation of STAT3 and Src activity using an active component of Antrodia cinnamomea mycelia

Chang¹,

Chen²,

Chen

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Ergone isolated from P. umbellatus prevented early renal injury in a rat model of nephropathy [23] and may play a central role in the effect exerted by choreito. Pollakisuria was ameliorated in 93% of patients who received choreito for lower urinary tract symptoms in an open-label, single-arm study of 30 patients [24].…”

Section: Discussionmentioning

confidence: 99%

Choreito Formula for BK Virus–associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation

Kawashima

Ito

Sekiya

et al. 2015

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Therapy for BK virus (BKV)-associated hemorrhagic cystitis (BKV-HC) is limited after hematopoietic stem cell transplantation (HSCT). We examined whether choreito, a formula from Japanese traditional Kampo medicine, is effective for treating BKV-HC. Among children who underwent allogeneic HSCT between October 2006 and March 2014, 14 were diagnosed with BKV-HC (median, 36 days; range, 14 to 330 days) after HSCT, and 6 consecutive children received pharmaceutical-grade choreito extract granules. The hematuria grade before treatment was significantly higher in the choreito group than in the nonchoreito group (P = .018). The duration from therapy to complete resolution was significantly shorter in the choreito group (median, 9 days; range, 4 to 17 days) than in the nonchoreito group (median, 17 days; range, 15 to 66 days; P = .037). In 11 children with macroscopic hematuria, the duration from treatment to resolution of macroscopic hematuria was significantly shorter in the choreito group than in the nonchoreito group (median, 2 days versus 11 days; P = .0043). The BKV load in urine was significantly decreased 1 month after choreito administration. No adverse effects related to choreito administration were observed. Choreito may be a safe and considerably promising therapy for the hemostasis of BKV-HC after HSCT.

show abstract

“…Excessive eryptosis may, however lead to anemia, a known side effect of Aristolochic Acid [20][21][22][23][24][25][26][27][28][29][30][31]. Phosphatidylserine exposing erythrocytes are rapidly cleared from circulating blood [32].…”

Section: Discussionmentioning

confidence: 99%

“…Aristolochic Acid is considered to be at least partially effective by inducing DNA adduct formation and mutations [1,4,8,9,13,14]. Aristolochic acid nephropathy is associated with anemia [20][21][22][23][24][25][26][27][28][29][30][31].…”

Section: Introductionmentioning

confidence: 99%

Aristolochic Acid Induced Suicidal Erythrocyte Death

Malik

Bissinger²,

Calabrò³

et al. 2014

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

Ergosta-4,6,8(14),22-tetraen-3-one isolated fromPolyporus umbellatusprevents early renal injury in aristolochic acid-induced nephropathy rats

Abstract: Ergone treatment conferred protection against early renal injury in a rat model of AA nephropathy. Early administration of ergone may prevent the progression of renal injury and the subsequent renal fibrosis in AA nephropathy.

Cited by 54 publications

References 32 publications

Targeting cancer initiating cells by promoting cell differentiation and restoring chemosensitivity via dual inactivation of STAT3 and Src activity using an active component of Antrodia cinnamomea mycelia

Targeting cancer initiating cells by promoting cell differentiation and restoring chemosensitivity via dual inactivation of STAT3 and Src activity using an active component of Antrodia cinnamomea mycelia

Choreito Formula for BK Virus–associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation

Aristolochic Acid Induced Suicidal Erythrocyte Death

Contact Info

Product

Resources

About